Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

计划入组 576 人 · 首次发布于 2017 年 12 月 13 日

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research

计划入组 567 人 · 首次发布于 2017 年 12 月 13 日

PK/PD Study of Gan & Lee Insulin Aspart Injection vs. US & EU NovoLog®/NovoRapid® in Healthy Males

计划入组 36 人 · 首次发布于 2020 年 1 月 23 日

Recombinant insulin glargine(Gan & Lee Pharmaceuticals Co., Ltd.)

GZR33

Insulin lispro protamine biosimilar(Gan & Lee Pharmaceuticals Co., Ltd.)

Gan & Lee Pharmaceuticals Co.,Ltd

China

Gan & Lee Pharmaceuticals USA Corporation

United States

CHANG HEE LEE

Australia

Gan & Lee Receives FDA Clearance for Phase II Trial of GZR18 in Obesity and Type 2 Diabetes

Gan & Lee Pharmaceuticals Partners with Brazil to Localize Insulin Production in Landmark Agreement

Gan & Lee's Novel Diabetes Drugs GZR18, GZR4, and GZR101 Achieve Positive Phase 2 Results